JAK2 and essential thrombocythemia: Those ET patients with the highest risk of thrombosis as measured by the IPSET-t score (based on age, thrombosis history, JAK2 V617F mutational status and cardiovascular risk factors) also had a paradoxical 4.2-fold increased bleeding risk (p = 0.003) when compared to lower risk categories [30].